文献速递神经肿瘤

高龄高级别胶质瘤患者接受同步放化疗的影响因素分析:简易精神状态检查、年龄与肿瘤体积的作用

Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume.
PubMed 文献 · J Neurooncol · 2017-07-06

该回顾性研究分析了117例≥65岁高级别胶质瘤患者,评估术前简易精神状态检查(MMSE)、年龄、性别、卡氏功能状态评分(KPS)、肿瘤体积对术后接受放化疗的影响。84例接受辅助治疗,中位年龄71岁、中位MMSE 26分、中位肿瘤体积24 cm³;接受辅助治疗者中位总生存期13个月,未接受者为5个月。MMSE、年龄和肿瘤体积可预测术后辅助治疗的可及性,接受同步放化疗者总生存期显著更长。

要点

  • 高龄高级别胶质瘤患者中,MMSE、年龄和肿瘤体积可预测术后辅助治疗的可及性。
  • 接受术后放化疗的高龄患者中位总生存期为13个月,未接受者为5个月。
  • 共117例≥65岁患者入组,其中84例接受了辅助治疗。

核心结论

  • 在高龄高级别胶质瘤患者中,MMSE、年龄和肿瘤体积可预测术后接受辅助治疗的可能性。
  • 接受术后放化疗的高龄高级别胶质瘤患者总生存期显著更长。

研究设计与样本

  • 回顾性分析本机构连续收治的117例≥65岁高级别胶质瘤患者。
  • 分析年龄、性别、肿瘤位置、MMSE、KPS、辅助治疗可及性和总生存期等临床记录。

主要发现

  • 共纳入72例男性和45例女性,中位年龄71岁。
  • 84例患者接受了辅助治疗。
  • 接受辅助治疗者的中位年龄为71岁(范围66-80岁),中位MMSE为26分(范围5-30分),中位肿瘤体积为24 cm³(范围1-140 cm³)。
  • 接受辅助治疗者的中位总生存期为13个月,未接受者为5个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High grade gliomas (HGG) are tumors with a rapidly progressive course and the standard of care consists of surgery and chemo-radiotherapy. Elderly patients with HGG usually have a worse prognosis due to their comorbidities and difficulties in accessing or completing adjuvant treatments. The purpose of our study was to assess the influence of pre-operative factors (MMSE, age, sex, KPS, tumor volume) on the post-operative access to chemo-radiotherapy in the elderly population. In addition, the influence of the access to adjuvant therapies on overall survival (OS) was assessed. We retrospectively reviewed our consecutive case series of 117 elderly patients (≥65 years) with HGG treated in our Institution. All the clinical records regarding age, sex, tumor location, MMSE, KPS, access to adjuvant treatments and OS were analyzed. 72 males and 45 females with a median age of 71 years were analyzed. Adjuvant therapies were considered; concomitant chemo-radiotherapy with standard radiotherapy or hypofractionated radiation regimen. 84 patients had access to adjuvant therapies. Access to therapies was associated with a median age of 71(range 66-80) years, a median MMSE of 26(range 5-30), and a median tumor volume of 24 cm3(range 1-140). The median OS was 13 months for patients who had access to adjuvant therapies and 5 months for patients who did not. In the elderly patients with HGG, the MMSE, age and tumor volume were predictive of post-surgery access to adjuvant treatments. OS was significantly longer in elderly patients with HGG who had access to post-surgery chemo-radiotherapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Di Cristofori A, Zarino B, Fanizzi C, et al. Analysis of factors influencing the access to concomitant chemo-radiotherapy in elderly patients with high grade gliomas: role of MMSE, age and tumor volume. J Neurooncol. 2017. PMID: 28685404. doi:10.1007/s11060-017-2537-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。